2-二甲氧基磷酰基-2-(苯基甲氧基羰基氨基)乙酸 | 89525-07-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-二甲氧基磷酰基-2-(苯基甲氧基羰基氨基)乙酸
• 英文名称: 2-benzyloxycarbonylamino-2-(dimethoxyphosphinyl)acetic acid
• 英文别名: Acetic acid, (dimethoxyphosphinyl)[[(phenylmethoxy)carbonyl]amino]-；2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetic acid
• CAS: 89525-07-5
• 化学式: C₁₂H₁₆NO₇P
• 分子量: 317.235
• InChiKey: RTXDKVFNAOMDFV-UHFFFAOYSA-N

物化性质

• 沸点：
  509.3±50.0 °C(Predicted)
• 密度：
  1.364±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  111
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-二甲氧基磷酰基-2-(苯基甲氧基羰基氨基)乙酸 在 palladium on activated charcoal N-甲基吗啉 、 氢气 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 25.0 ℃ 、303.38 kPa 条件下， 反应 4.0h， 生成 di-tert-butyl N-<2-(acetylamino)-2-(dimethoxyphosphinyl)acetyl>-L-glutamate
  参考文献：
  名称：

  Synthesis of acyclic and dehydroaspartic acid analogs of Ac-Asp-Glu-OH and their inhibition of rat brain N-acetylated .alpha.-linked acidic dipeptidase (NAALA dipeptidase)

  摘要：

  The following structural and conformationally constrained analogues of Ac-Asp-Glu-OH (1) were synthesized: Ac-Glu-Glu-OH (2), Ac-D-Asp-Glu-OH (3), Ac-Glu-Asp-OH (4), Ac-Asp-Asp-OH (5), Ac-Asp-3-aminohexanedioic acid (6), Ac-3-amino-3-(carboxymethyl)propanoyl-Glu-OH (7), N-succinyl-Glu-OH (8), N-maleyl-Glu-OH (9), N-fumaryl-Glu-OH (10), and Ac-delta ZAsp-Glu-OH (11). These analogues were evaluated for their ability to inhibit the hydrolysis of Ac-Asp-[3,4-3H]-Glu-OH by N-acetylated alpha-linked acidic dipeptidase (NAALA dipeptidase) in order to gain some insight into the structural requirements for the inhibition of this enzyme. Analogues 4-6 and 9 were very weak inhibitors of NAALA dipeptidase (Ki greater than 40 microM), while 2, 3, and 7 with Ki values ranging from 3.2-8.5 microM showed intermediate inhibitory activity. The most active inhibitors of NAALA dipeptidase were compounds 8, 10, and 11 with Ki values of 0.9, 0.4, and 1.4 microM, respectively. These results suggest that the relative spacing between the side chain carboxyl and the alpha-carboxyl group of the C-terminal residue may be important for binding to the active site of the enzyme. They also indicate that the chi 1 torsional angle for the aspartyl residue is in the vicinity of 0 degrees.

  DOI：

  10.1021/jm00172a009
• 作为产物：
  描述：

  methyl 2-(benzyloxycarbonylamino)-2-methoxyacetate 在 sodium hydroxide 、 三氯化磷 作用下， 以 1,4-二氧六环 为溶剂， 反应 20.0h， 生成 2-二甲氧基磷酰基-2-(苯基甲氧基羰基氨基)乙酸
  参考文献：
  名称：

  Amino Acids and Peptides; XLIII¹. Dehydroamino Acids; XVIII². Synthesis of Dehydroamino Acids and Amino Acids fromN-Acyl-2-(dialkyloxyphosphinyl)-glycin Esters; II

  摘要：

  DOI：

  10.1055/s-1984-30730

文献信息

• [EN] PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'ACIDE PHOSPHONIQUE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DU RÉCEPTEUR P2Y12
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2009069100A1

  公开（公告）日：2009-06-04

  The invention relates to 2-phenyl-pyrimidine derivatives containing a phosphonic acid motif and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. (I).

  这项发明涉及含有膦酸基团的2-苯基嘧啶衍生物，以及它们作为P2Y12受体拮抗剂在治疗和/或预防外周血管、内脏-、肝脏和肾脏血管、心血管和脑血管疾病或与血小板聚集有关的疾病或状况中的使用，包括人类和其他哺乳动物中的血栓形成。（I）。
• Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease
  申请人：——

  公开号：US20030105089A1

  公开（公告）日：2003-06-05

  The invention provides compounds of Formula I: 1 which may be in the form of pharmaceutical acceptable salts or compositions, are useful in treating diseases or conditions in which &agr;7 nicotinic acetylcholine receptors (nAChRs) are known to be involved.

  这项发明提供了Formula I的化合物： 1 这些化合物可以是药用可接受的盐或组合物的形式，对治疗涉及α7尼古丁型乙酰胆碱受体(nAChRs)的疾病或症状是有用的。
• [EN] TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER<br/>[FR] PRODUITS RADIOPHARMACEUTIQUES CIBLÉS POUR LE DIAGNOSTIC ET LE TRAITEMENT DU CANCER DE LA PROSTATE
  申请人：BAYER AS

  公开号：WO2021013978A1

  公开（公告）日：2021-01-28

  A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.

  通用式(I)的化合物：其中：n为1、2或3；R1、R2、R3和R4独立地代表OH或Q；Q代表从群组中选择的组织靶向基团，或其立体异构体、水合物、溶剂合物、盐或其混合物，制备所述化合物的方法，用于制备所述化合物的中间化合物，包含所述化合物的药物组合物和组合物，以及用于制造用于治疗或预防疾病的药物组合物的所述化合物的用途，特别是软组织疾病的治疗或预防，作为唯一药剂或与其他活性成分结合使用。
• [EN] MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS<br/>[FR] ANTIBIOTIQUES MACROCYCLIQUES À LARGE SPECTRE
  申请人：RQX PHARMACEUTICALS INC

  公开号：WO2018149419A1

  公开（公告）日：2018-08-23

  Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

  本文提供了抗菌化合物，其中在某些实施例中，这些化合物具有广谱生物活性。在各种实施例中，这些化合物通过抑制细菌类型1信号肽酶（SpsB）发挥作用，这是细菌中的一种必需蛋白质。还提供了使用所述化合物的药物组合物和治疗方法。
• SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES
  申请人：Caroff Eva

  公开号：US20110046089A1

  公开（公告）日：2011-02-24

  The present invention relates to compounds of formula I wherein R 1 , R 2 , R 4 , R 5 , R a , R b , n, W and Z are as defined in the application, their preparation and their use as P2Y 12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

  本发明涉及式I化合物的制备及其用途，式中R1、R2、R4、R5、Ra、Rb、n、W和Z的定义如申请中所述，以及它们作为P2Y12受体拮抗剂用于治疗和/或预防外周血管、内脏血管、肝脏血管和肾脏血管、心血管和脑血管疾病或与血小板聚集相关状况的用途，包括人类和其他哺乳动物中的血栓症。